Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study

Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, plac...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Scientific reports Ročník 14; číslo 1; s. 3149 - 12
Hlavní autori:	Armand, Sophia, Langley, Christelle, Johansen, Annette, Ozenne, Brice, Overgaard-Hansen, Oliver, Larsen, Kristian, Jensen, Peter Steen, Knudsen, Gitte Moos, Sahakian, Barbara Jacquelyn, Stenbæk, Dea Siggard, Fisher, Patrick MacDonald
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 07.02.2024 Nature Publishing Group Nature Portfolio
Predmet:	631/154/436 631/378/1457 631/378/2649 Amygdala Brain mapping Brain research Citalopram Clinical trials Cognition & reasoning Emotions Face Females Functional magnetic resonance imaging Health care Hospitals Humanities and Social Sciences Investigations Mood multidisciplinary NCT NCT04239339 Placebos Science Science (multidisciplinary) Serotonin Serotonin uptake inhibitors
ISSN:	2045-2322, 2045-2322
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3–5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen’s D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3–5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen’s D\|< 0.2, P FWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen’s D\|< 0.6, P FWER < .01) and occipital regions (\|Cohen’s D\|< 0.5, P FWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3–5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI’s therapeutic efficacy. Trial registration Clinical Trials NCT04239339.
AbstractList	Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3–5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen’s D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3–5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen’s D\|< 0.2, PFWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen’s D\|< 0.6, PFWER < .01) and occipital regions (\|Cohen’s D\|< 0.5, PFWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3–5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI’s therapeutic efficacy. Trial registration Clinical Trials NCT04239339. Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3–5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen’s D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3–5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen’s D\|< 0.2, PFWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen’s D\|< 0.6, PFWER < .01) and occipital regions (\|Cohen’s D\|< 0.5, PFWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3–5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI’s therapeutic efficacy.Trial registration Clinical Trials NCT04239339. Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3–5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen’s D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3–5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen’s D\|< 0.2, P FWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen’s D\|< 0.6, P FWER < .01) and occipital regions (\|Cohen’s D\|< 0.5, P FWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3–5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI’s therapeutic efficacy. Trial registration Clinical Trials NCT04239339. Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3-5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen's D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3-5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen's D\|< 0.2, P = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen's D\|< 0.6, P < .01) and occipital regions (\|Cohen's D\|< 0.5, P < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3-5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI's therapeutic efficacy.Trial registration Clinical Trials NCT04239339. Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3-5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen's D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3-5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen's D\|< 0.2, PFWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen's D\|< 0.6, PFWER < .01) and occipital regions (\|Cohen's D\|< 0.5, PFWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3-5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI's therapeutic efficacy.Trial registration Clinical Trials NCT04239339.Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3-5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen's D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3-5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen's D\|< 0.2, PFWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen's D\|< 0.6, PFWER < .01) and occipital regions (\|Cohen's D\|< 0.5, PFWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3-5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI's therapeutic efficacy.Trial registration Clinical Trials NCT04239339. Abstract Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI intake over a clinically relevant time period modulates threat-related amygdala responses is less clear. In a semi-randomised, double-blind, placebo-controlled study of 64 healthy individuals (SSRI n = 32, placebo n = 32), we examined the effect of 3–5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, fearful and neutral faces using BOLD fMRI. Data was analysed using a whole-brain region-wise approach extracting standardised effects (i.e., Cohen’s D). The study was conducted at the Copenhagen University Hospital. A priori, we hypothesised that SSRI would attenuate amygdala responses to angry and fearful faces but not to neutral ones. Whether SSRI modulates correlations between amygdala responses to emotional faces and negative mood states was also explored. Compared to placebo, 3–5 weeks of SSRI intake did not significantly affect the amygdala response to angry, fearful, or neutral faces (\|Cohen’s D\|< 0.2, P FWER = 1). Whole-brain, region-wise analyses revealed significant differences in frontal (\|Cohen’s D\|< 0.6, P FWER < .01) and occipital regions (\|Cohen’s D\|< 0.5, P FWER < .01). SSRI did not modulate correlations between amygdala responses to emotional faces and negative mood states. Our findings indicate that a 3–5 week SSRI intake impacts cortical responses to emotional stimuli, an effect possibly involved in SSRI’s therapeutic efficacy. Trial registration Clinical Trials NCT04239339.
ArticleNumber	3149
Author	Jensen, Peter Steen Langley, Christelle Fisher, Patrick MacDonald Stenbæk, Dea Siggard Armand, Sophia Johansen, Annette Ozenne, Brice Overgaard-Hansen, Oliver Larsen, Kristian Sahakian, Barbara Jacquelyn Knudsen, Gitte Moos
Author_xml	– sequence: 1 givenname: Sophia surname: Armand fullname: Armand, Sophia organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Psychology, Faculty of Social Sciences, University of Copenhagen – sequence: 2 givenname: Christelle surname: Langley fullname: Langley, Christelle organization: Department of Psychiatry, University of Cambridge – sequence: 3 givenname: Annette surname: Johansen fullname: Johansen, Annette organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 4 givenname: Brice surname: Ozenne fullname: Ozenne, Brice organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Section of Biostatistics, Department of Public Health, University of Copenhagen – sequence: 5 givenname: Oliver surname: Overgaard-Hansen fullname: Overgaard-Hansen, Oliver organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet – sequence: 6 givenname: Kristian surname: Larsen fullname: Larsen, Kristian organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 7 givenname: Peter Steen surname: Jensen fullname: Jensen, Peter Steen organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet – sequence: 8 givenname: Gitte Moos surname: Knudsen fullname: Knudsen, Gitte Moos organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 9 givenname: Barbara Jacquelyn surname: Sahakian fullname: Sahakian, Barbara Jacquelyn organization: Department of Psychiatry, University of Cambridge – sequence: 10 givenname: Dea Siggard surname: Stenbæk fullname: Stenbæk, Dea Siggard email: dea@nru.dk organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Psychology, Faculty of Social Sciences, University of Copenhagen – sequence: 11 givenname: Patrick MacDonald surname: Fisher fullname: Fisher, Patrick MacDonald organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38326352$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1v1DAUjFARLaV_gAOyxIUDAccfWYdLhSoKlSpx6d1y7Oddb732YieL9kfxH3GaLbQ91Jc8vTcznvjN6-ooxABV9bbBnxpMxefMGt6JGhNW84YxUZMX1QnBjNeEEnL0oD6uznJe43I46VjTvaqOqaCkpZycVH8ux6AHF4PyqE_KBZQgb2PIkNEQEWziYWiVLi1lB0hoWCWAaWzdDtBvgNuMokUuDOoWpgqydoPycZvUprTRCpQfVvtSGrdzZlQ-f0EKmTj2Hurel_5HtPXlij7WOoYhRe_BoKSCiRuXS5mH0ezfVC9t4cLZ4Xta3Vx-u7n4UV___H518fW61pw1Q923rBfAFoA1hxZbg1uibaeanlpDAWNqBWOdoF3HBBZdA9RQyhVWesEB6Gl1NcuaqNZym9xGpb2Mysm7RkxLqdLgtAdprCCMYQxKWcYXuicLLBbK2rIkbPumaJ3PWtux34DRUH5O-UeijyfBreQy7mSDBccci6Lw4aCQ4q8R8iDLi2jwXgWIY5akI7RrChQX6Psn0HUcU1nfjGoExm1bUO8eWvrn5T4VBSBmgE4x5wRWTuucglAcOl-sySmDcs6gLBmUdxmUE5U8od6rP0uiMykXcFhC-m_7GdZfe9nxxg
CitedBy_id	crossref_primary_10_1038_s41467_025_63078_x crossref_primary_10_1016_j_pnpbp_2025_111470
Cites_doi	10.1001/archpsyc.61.12.1271 10.1016/j.cpr.2020.101842 10.1177/0956797620916786 10.1038/mp.2013.147 10.1016/S0006-3223(98)00139-5 10.1177/02698811221089035 10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-7 10.1080/17470910802571633 10.2174/1871527313666141130205713 10.1007/s00213-019-05448-0 10.1016/j.neuroimage.2005.05.039 10.1177/0269881115620462 10.1016/j.neuroimage.2008.05.049 10.1186/2045-5380-1-2 10.1016/j.neubiorev.2020.09.001 10.1016/j.biopsych.2005.10.015 10.1016/j.jpsychores.2016.03.009 10.1038/npp.2010.77 10.1192/bjp.bp.108.051193 10.1016/j.neuropharm.2020.108155 10.1016/j.euroneuro.2021.10.484 10.1093/scan/nsv098 10.1038/npp.2017.166 10.1098/rstb.2012.0407 10.1016/j.neuroimage.2009.10.013 10.1001/archpsyc.59.7.597 10.1097/01.jcp.0000168879.03169.ce 10.31887/dcns.2010.12.4/ycharnay 10.1111/j.1559-1816.2012.00900.x 10.1016/j.biopsych.2013.11.031 10.1016/j.neuroimage.2003.09.032 10.1038/npp.2015.187 10.2165/00003088-200746040-00002 10.1038/sj.npp.1300728 10.1038/sj.mp.4000812 10.1007/s00213-018-5158-3 10.1016/j.cpr.2015.12.003 10.1016/j.cortex.2018.03.011 10.1177/0269881113494106.Acute 10.1097/01.yic.0000194375.42589.c3 10.1177/1529100619850176 10.1098/rstb.2010.0351 10.1037/1040-3590.10.2.83 10.1097/WNR.0b013e3282742115 10.1016/j.neuropsychologia.2010.06.038 10.1017/S1461145708009164 10.1016/j.neuropsychologia.2007.01.023 10.1007/s00213-007-1004-8.Escitalopram 10.1186/s12874-020-00982-4 10.1037/t06496-000 10.1016/S0925-4927(97)00063-2 10.1038/s41386-022-01523-x 10.1016/j.neuroimage.2012.01.129 10.1038/npp.2014.339 10.1093/scan/nsm029 10.1016/j.jneumeth.2006.10.016 10.1523/JNEUROSCI.1175-07.2007 10.1016/S1053-8119(03)00169-1 10.1080/17470919.2017.1421262 10.1016/S0006-3223(01)01330-0 10.1016/j.neuroimage.2015.04.025 10.1038/npp.2008.52 10.1111/j.1749-6632.2010.05445.x 10.1192/bjp.bp.108.056093 10.1186/2045-5380-1-10
ContentType	Journal Article
Copyright	The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.1038/s41598-024-51448-2
DatabaseName	Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database (ProQuest) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database CrossRef PubMed MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2045-2322
EndPage	12
ExternalDocumentID	oai_doaj_org_article_df824400eaaf457cb27087aff1030fb1 PMC10850508 38326352 10_1038_s41598_024_51448_2
Genre	Journal Article
GrantInformation_xml	– fundername: NIHR Cambridge Biomedical Research Centre grantid: BRC-1215-20014 funderid: http://dx.doi.org/10.13039/501100018956 – fundername: Lundbeckfonden grantid: R281-2018-131 funderid: http://dx.doi.org/10.13039/501100003554 – fundername: NIHR Applied Research Centre – fundername: NIHR Cambridge Biomedical Research Centre grantid: BRC-1215-20014 – fundername: Lundbeckfonden grantid: R281-2018-131
GroupedDBID	0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c541t-b64b8e47e0c5e60fd062cf9a1b3fd3e003f84498399480891e3d335a0ac75ee3
IEDL.DBID	DOA
ISICitedReferencesCount	2
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001158921600022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2045-2322
IngestDate	Fri Oct 03 12:52:30 EDT 2025 Tue Nov 04 02:05:47 EST 2025 Fri Sep 05 09:33:29 EDT 2025 Tue Oct 07 08:25:45 EDT 2025 Mon Jul 21 06:00:35 EDT 2025 Tue Nov 18 22:07:10 EST 2025 Sat Nov 29 01:57:09 EST 2025 Fri Feb 21 02:38:55 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c541t-b64b8e47e0c5e60fd062cf9a1b3fd3e003f84498399480891e3d335a0ac75ee3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
OpenAccessLink	https://doaj.org/article/df824400eaaf457cb27087aff1030fb1
PMID	38326352
PQID	2923180066
PQPubID	2041939
PageCount	12
ParticipantIDs	doaj_primary_oai_doaj_org_article_df824400eaaf457cb27087aff1030fb1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10850508 proquest_miscellaneous_2923910500 proquest_journals_2923180066 pubmed_primary_38326352 crossref_citationtrail_10_1038_s41598_024_51448_2 crossref_primary_10_1038_s41598_024_51448_2 springer_journals_10_1038_s41598_024_51448_2
PublicationCentury	2000
PublicationDate	2024-02-07
PublicationDateYYYYMMDD	2024-02-07
PublicationDate_xml	– month: 02 year: 2024 text: 2024-02-07 day: 07
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Scientific reports
PublicationTitleAbbrev	Sci Rep
PublicationTitleAlternate	Sci Rep
PublicationYear	2024
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	ArmourCMűllerováJElhaiJDA systematic literature review of PTSD’s latent structure in the diagnostic and statistical manual of mental disorders: DSM-IV to DSM-5Clin. Psychol. Rev.201644607410.1016/j.cpr.2015.12.00326761151 NielsenMGØrnbølEVestergaardMThe construct validity of the perceived stress scaleJ. Psychosom. Res.201584223010.1016/j.jpsychores.2016.03.009 SaidCPHaxbyJVTodorovABrain systems for assessing the affective value of facesPhilos. Trans. R. Soc. B Biol. Sci.201136615711660167010.1098/rstb.2010.0351 BigosKLPollockBGAizensteinHJFisherPMBiesRRHaririARAcute 5-HT reuptake blockade potentiates human amygdala reactivityNeuropsychopharmacology20083313322132251:CAS:528:DC%2BD1cXhtlCktbvO10.1038/npp.2008.5218463627 MaronEWallMNorburyREffect of short-term escitalopram treatment on neural activation during emotional processingJ. Psychopharmacol.201630133391:CAS:528:DC%2BC28XhsVCktL3O10.1177/026988111562046226645207 FisherPMHaahrMEJensenCGFrokjaerVGFluctuations in [11 C] SB207145 PET binding associated with change in threat-related amygdala reactivity in humansNeuropsychopharmacology2015406151015181:CAS:528:DC%2BC2MXhvVOmtr4%3D10.1038/npp.2014.339255602014397409 NyenhuisDLYamamotoCLuchetaTTerrienAParmentierAAdult and geriatric normative data and validation of the profile of mood statesJ. Clin. Psychol.199955179861:STN:280:DyaK1M7pvV2gsQ%3D%3D10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-710100834 CowenASauterDTracyJLKeltnerDMapping the passions: Toward a high-dimensional taxonomy of emotional experience and expressionPsychol. Sci. Public Interest2019201699010.1177/1529100619850176313136376675572 BanksSJEddyKTAngstadtMNathanPJLuanPKAmygdala-frontal connectivity during emotion regulationSoc. Cogn. Affect. Neurosci.20072430331210.1093/scan/nsm029189851362566753 AdolphsRWhat does the amygdala contribute to social cognition?Ann. NY Acad. Sci.20101191142612010NYASA1191...42A10.1111/j.1749-6632.2010.05445.x20392275 SchneiderFGroddWWeissUFunctional MRI reveals left amygdala activation during emotionPsychiatry Res. Neuroimaging1997762–375821:STN:280:DyaK1c7ot1yksg%3D%3D10.1016/S0925-4927(97)00063-2 CohenSJanicki-DevertsDWho’s stressed? Distributions of psychological stress in the United States in probability samples from 1983, 2006, and 2009J. Appl. Soc. Psychol.20124261320133410.1111/j.1559-1816.2012.00900.x McNair, D., Lorr, M. & Droppleman, L. Manual for the Profile of Mood States. (Service E and IT, ed.). (1992) Taylor TavaresJVClarkLFureyMLWilliamsGBSahakianBJDrevetsWCNeural basis of abnormal response to negative feedback in unmedicated mood disordersNeuroimage20084231118112610.1016/j.neuroimage.2008.05.04918586109 Fusar-PoliPPlacentinoACarlettiFFunctional atlas of emotional faces processing: A voxel-based meta-analysis of 105 functional magnetic resonance imaging studiesJ. Psychiatry Neurosci.2009346418432199497182783433 WindischbergerCLanzenbergerRHolikAArea-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over studyNeuroimage2010492116111701:CAS:528:DC%2BC3cXltFGgsL8%3D10.1016/j.neuroimage.2009.10.01319833214 MiskowiakKWCarvalhoAF‘Hot’ cognition in major depressive disorder: A systematic reviewCNS Neurol. Disord. Drug Targets201513101787180310.2174/1871527313666141130205713 KnudsenGMJensenPSErritzoeDThe center for integrated molecular brain imaging (Cimbi) databaseNeuroimage20161241213121910.1016/j.neuroimage.2015.04.02525891375 GodlewskaBRHarmerCJCognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatmentPsychopharmacology (Berl)20202385126512781:CAS:528:DC%2BB3cXis1SjtL4%3D10.1007/s00213-019-05448-031938879 ElliottRZahnRDeakinJFWWAndersonIMAffective cognition and its disruption in mood disordersNeuropsychopharmacology201136115318210.1038/npp.2010.7720571485 LangleyCArmandSLuoQChronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: A double-blind, placebo-controlled semi-randomised studyNeuropsychopharmacology202310.1038/s41386-022-01523-x3791489310789782 MoserEDerntlBRobinsonSFinkBGurRCGrammerKAmygdala activation at 3T in response to human and avatar facial expressions of emotionsJ. Neurosci. Methods2007161112613310.1016/j.jneumeth.2006.10.01617126910 FisherPMMadsenMKMc MahonBThree-week bright-light intervention has dose-related effects on threat-related corticolimbic reactivity and functional couplingBiol. Psychiatry201476433233910.1016/j.biopsych.2013.11.03124439303 DavisMWhalenPJThe amygdala: Vigilance and emotionMol. Psychiatry20016113341:STN:280:DC%2BD3M3ktlWrtg%3D%3D10.1038/sj.mp.400081211244481 FisherPMPriceJCMeltzerCCMedial prefrontal cortex serotonin 1A and 2A receptor binding interacts to predict threat-related amygdala reactivityBiol. Mood Anxiety Disord.2011111111:CAS:528:DC%2BC38Xlt12htrk%3D10.1186/2045-5380-1-2 HaxbyJVHoffmanEAGobbiniMIHuman neural systems for face recognition and social communicationBiol. Psychiatry2002511596710.1016/S0006-3223(01)01330-011801231 KasperSSpadoneCVerpillatPAngstJOnset of action of escitalopram compared with other antidepressants: Results of a pooled analysisInt. Clin. Psychopharmacol.200621210511010.1097/01.yic.0000194375.42589.c316421462 Del-BenCMDeakinJFWMckieSThe effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: An fMRI studyNeuropsychopharmacology2005309172417341:CAS:528:DC%2BD2MXotFegurY%3D10.1038/sj.npp.130072815827569 MeyerJHHouleSSagratiSBrain serotonin transporter binding potential measured with Carbon11–labeled DASB positron emission tomographyArch. Gen. Psychiatry2004611212711:CAS:528:DC%2BD2MXjt1Kmtw%3D%3D10.1001/archpsyc.61.12.127115583118 KatzBAMatankyKAviramGYovelIReinforcement sensitivity, depression and anxiety: A meta-analysis and meta-analytic structural equation modelClin. Psychol. Rev.20207710.1016/j.cpr.2020.10184232179341 ElliottRRubinszteinJSSahakianBJDolanRJThe neural basis of mood-congruent processing biases in depressionArch. Gen. Psychiatry200259759760410.1001/archpsyc.59.7.59712090812 HarmerCJMackayCEReidCBCowenPJGoodwinGMAntidepressant drug treatment modifies the neural processing of nonconscious threat cuesBiol. Psychiatry20065998168201:CAS:528:DC%2BD28XjsFOnt7w%3D10.1016/j.biopsych.2005.10.01516460693 AndersonIMDel-BenCMMcKieSCitalopram modulation of neuronal responses to aversive face emotions: A functional MRI studyNeuroreport20071813135113551:CAS:528:DC%2BD2sXpvVajtrk%3D10.1097/WNR.0b013e328274211517762711 HornbollBMacoveanuJRoweJElliottRAcute 5-HT 2A receptor blocking alters the processing of fearful faces in orbitofrontal cortex and amygdalaJ. Pharmacol. Pharomotherapeutics.2015271090391410.1177/0269881113494106.Acute StuhrmannASuslowTDannlowskiUFacial emotion processing in major depression: A systematic review of neuroimaging findingsBiol. Mood Anxiety Disord.20111111010.1186/2045-5380-1-10 da Cunha-BangSFisherPMHjordtLVHolstKKnudsenGMAmygdala reactivity to fearful faces correlates positively with impulsive aggressionSoc. Neurosci.201914216217210.1080/17470919.2017.142126229271284 MeyerJHMcMainSKennedySHDysfunctional attitudes and 5-HT2 receptors during depression and self-harmPsychiatry Interpers Biol. Process.2003160January9099 GustafsonLWGabelPHammerAValidity and reliability of state-trait anxiety inventory in danish women aged 45 years and older with abnormal cervical screening resultsBMC Med. Res. Methodol.20202011910.1186/s12874-020-00982-4 KhanABrodheadAESchwartzKAKoltsRLBrownWASex differences in antidepressant response in recent antidepressant clinical trialsJ. Clin. Psychopharmacol.200525431832410.1097/01.jcp.0000168879.03169.ce16012273 MaldjianJALaurientiPJBurdetteJHPrecentral gyrus discrepancy in electronic versions of the Talairach atlasNeuroimage200421145045510.1016/j.neuroimage.2003.09.03214741682 MüllerVIHöhnerYEickhoffSBInfluence of task instructions and stimuli on the neural network of face processing: An ALE meta-analysisCortex201810324025510.1016/j.cortex.2018.03.011296654675988961 PlichtaMMSchwarzAJGrimmOTest-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test batteryNeuroimage20126031746175810.1016/j.neuroimage.2012.01.12922330316 RaoNThe clinical pharmacokinetics of escitalopramClin. Pharmacokinet.20074642812901:CAS:528:DC%2BD2sXlt1Grsrs%3D10.2165/00003088-200746040-0000217375980 FitzgeraldDAAngstadtMJelsoneLMNathanPJPhanKLBeyond threat: Amygdala reactivity across multiple expressions of facial affectNeuroImage (Orlando, Fla)200630414411448 Reynolds, C. R. & Kamphaus, R.W. RIAS/RIST : Reynolds Intellectual Assessment Scales, Reynolds Intellectual Screening Test : Vejledning. 1. oplag. (Hogrefe Psykologisk Forlag, 2011). HabelUWindischbergerCDerntlBAmygdala activation and facial expressions: Explicit emotion discrimination versus implicit emotion processingNeuropsychologia.200745102369237710.1016/j.neuropsychologia.2007.01.02317408704 RhodesRAMurthyNVDresnerMAHuman 5-HT transporter availability predicts amygdala reactivity in vivoJ. Neurosci.20072734923392371:CAS:528:DC%2BD2sXhtVSnsLfN10.1523/JNEUROSCI.1175-07.2007177153586672189 CharnayYLégerLBrain serotonergic circuitriesDialogues Clin. Neurosci.201012447148710.31887/dcns.2010.12.4/ycharnay213194933181988 ArceESimmonsANLoveroKSteinMBPaulusMPEsctilaopram effects on insula and amygdala BOLD during emotional processiengPsychopharmachology (Berl)200819646616721:CAS:528:DC%2BD1cXhvFykurw%3D10.1007/s00213-007-1004-8.Escitalopram HaahrMEFisherPMJensenCGCentral 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: A [11C]SB207145 PET studyMol. Psychiatry20141944274321:CAS:528:DC%2BC3sXhslCrtL%2FO10.1038/mp.2013.14724189342 MadsenMKMc MahonBAndersenSBSiebnerHRKnudsenGMFisherPMDThreat-related amygdala functional connectivity is associated with 5-HTTLPR genotype and neuroticismSoc. Cogn. Affect Neurosci.201511114014910.1093/scan/nsv098262458374692322 MaldjianJALaurientiPJKraftRABurdetteJHAn automated method for neuroanatomic and cytoarchit A Cowen (51448_CR3) 2019; 20 JV Haxby (51448_CR2) 2002; 51 KW Miskowiak (51448_CR18) 2015; 13 JH Meyer (51448_CR30) 2004; 61 B Derntl (51448_CR12) 2009; 4 GM Knudsen (51448_CR71) 2016; 124 VI Müller (51448_CR15) 2018; 103 S Cohen (51448_CR61) 2012; 42 LW Gustafson (51448_CR54) 2020; 20 Y Charnay (51448_CR31) 2010; 12 MG Nielsen (51448_CR55) 2015; 84 S Armand (51448_CR27) 2021; 53 I Lucki (51448_CR20) 1998; 44 ML Elliott (51448_CR69) 2020; 31 SE Murphy (51448_CR42) 2009; 12 PM Fisher (51448_CR35) 2022; 36 PM Fisher (51448_CR24) 2015; 40 CJ Harmer (51448_CR45) 2006; 59 C Langley (51448_CR49) 2023 BR Godlewska (51448_CR34) 2020; 238 M Davis (51448_CR11) 2001; 6 RA Rhodes (51448_CR28) 2007; 27 H Takahashi (51448_CR44) 2005; 27 51448_CR53 BA Katz (51448_CR62) 2020; 77 ME Haahr (51448_CR67) 2014; 19 51448_CR56 CM Del-Ben (51448_CR41) 2005; 30 MK Madsen (51448_CR29) 2015; 11 H Cremers (51448_CR37) 2016; 41 JA Maldjian (51448_CR59) 2003; 19 B Hornboll (51448_CR25) 2015; 27 C Windischberger (51448_CR39) 2010; 49 N Rao (51448_CR50) 2007; 46 51448_CR51 S Kasper (51448_CR32) 2006; 21 P Fusar-Poli (51448_CR5) 2009; 34 R Adolphs (51448_CR7) 2010; 1191 DL Nyenhuis (51448_CR57) 1999; 55 S Selvaraj (51448_CR36) 2018; 43 CJ Harmer (51448_CR19) 2013; 368 MM Plichta (51448_CR68) 2012; 60 U Habel (51448_CR14) 2007; 45 CP Said (51448_CR4) 2011; 366 E Moser (51448_CR10) 2007; 161 E Maron (51448_CR46) 2016; 30 JA Maldjian (51448_CR60) 2004; 21 PM Fisher (51448_CR23) 2011; 1 SE Murphy (51448_CR43) 2009; 194 JV Taylor Tavares (51448_CR63) 2008; 42 SJ Banks (51448_CR65) 2007; 2 E Arce (51448_CR47) 2008; 196 R Elliott (51448_CR64) 2002; 59 T Sharp (51448_CR21) 2020; 177 KL Bigos (51448_CR38) 2008; 33 A Khan (51448_CR48) 2005; 25 F Schneider (51448_CR13) 1997; 76 C Roberts (51448_CR22) 2020; 119 L Pessoa (51448_CR6) 2010; 48 R Elliott (51448_CR16) 2011; 36 S da Cunha-Bang (51448_CR17) 2019; 14 DA Fitzgerald (51448_CR8) 2006; 30 JH Meyer (51448_CR26) 2003; 160 PM Fisher (51448_CR58) 2014; 76 J Lansner (51448_CR70) 2019; 236 51448_CR1 C Armour (51448_CR9) 2016; 44 A Stuhrmann (51448_CR66) 2011; 1 CJ Harmer (51448_CR33) 2009; 195 DJA Dozois (51448_CR52) 1998; 10 IM Anderson (51448_CR40) 2007; 18
References_xml	– reference: BanksSJEddyKTAngstadtMNathanPJLuanPKAmygdala-frontal connectivity during emotion regulationSoc. Cogn. Affect. Neurosci.20072430331210.1093/scan/nsm029189851362566753 – reference: HornbollBMacoveanuJRoweJElliottRAcute 5-HT 2A receptor blocking alters the processing of fearful faces in orbitofrontal cortex and amygdalaJ. Pharmacol. Pharomotherapeutics.2015271090391410.1177/0269881113494106.Acute – reference: KnudsenGMJensenPSErritzoeDThe center for integrated molecular brain imaging (Cimbi) databaseNeuroimage20161241213121910.1016/j.neuroimage.2015.04.02525891375 – reference: MurphySEYiendJLesterKJCowenPJHarmerCJShort-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteersInt. J. Neuropsychopharmacol.20091221691791:CAS:528:DC%2BD1MXit1ahtrg%3D10.1017/S146114570800916418752726 – reference: WindischbergerCLanzenbergerRHolikAArea-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over studyNeuroimage2010492116111701:CAS:528:DC%2BC3cXltFGgsL8%3D10.1016/j.neuroimage.2009.10.01319833214 – reference: Reynolds, C. R. & Kamphaus, R.W. RIAS/RIST : Reynolds Intellectual Assessment Scales, Reynolds Intellectual Screening Test : Vejledning. 1. oplag. (Hogrefe Psykologisk Forlag, 2011). – reference: NielsenMGØrnbølEVestergaardMThe construct validity of the perceived stress scaleJ. Psychosom. Res.201584223010.1016/j.jpsychores.2016.03.009 – reference: GodlewskaBRHarmerCJCognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatmentPsychopharmacology (Berl)20202385126512781:CAS:528:DC%2BB3cXis1SjtL4%3D10.1007/s00213-019-05448-031938879 – reference: MoserEDerntlBRobinsonSFinkBGurRCGrammerKAmygdala activation at 3T in response to human and avatar facial expressions of emotionsJ. Neurosci. Methods2007161112613310.1016/j.jneumeth.2006.10.01617126910 – reference: LangleyCArmandSLuoQChronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: A double-blind, placebo-controlled semi-randomised studyNeuropsychopharmacology202310.1038/s41386-022-01523-x3791489310789782 – reference: GustafsonLWGabelPHammerAValidity and reliability of state-trait anxiety inventory in danish women aged 45 years and older with abnormal cervical screening resultsBMC Med. Res. Methodol.20202011910.1186/s12874-020-00982-4 – reference: PessoaLEmotion and cognition and the amygdala: From “what is it?” to “what’s to be done?”Neuropsychologia201048123416342910.1016/j.neuropsychologia.2010.06.038206192802949460 – reference: MiskowiakKWCarvalhoAF‘Hot’ cognition in major depressive disorder: A systematic reviewCNS Neurol. Disord. Drug Targets201513101787180310.2174/1871527313666141130205713 – reference: Ekman, P., Friesen, W.V. Unmasking the Face : A Guide to Recognizing Emotions from Facial Expressions. (Malor, 2003). – reference: BigosKLPollockBGAizensteinHJFisherPMBiesRRHaririARAcute 5-HT reuptake blockade potentiates human amygdala reactivityNeuropsychopharmacology20083313322132251:CAS:528:DC%2BD1cXhtlCktbvO10.1038/npp.2008.5218463627 – reference: StuhrmannASuslowTDannlowskiUFacial emotion processing in major depression: A systematic review of neuroimaging findingsBiol. Mood Anxiety Disord.20111111010.1186/2045-5380-1-10 – reference: ArmandSOzenneBSvartNBrain serotonin transporter is associated with cognitive affective biases in healthy individualsEur. Neuropsychopharmacol.202153AprilS377S37810.1016/j.euroneuro.2021.10.484 – reference: FitzgeraldDAAngstadtMJelsoneLMNathanPJPhanKLBeyond threat: Amygdala reactivity across multiple expressions of facial affectNeuroImage (Orlando, Fla)200630414411448 – reference: AndersonIMDel-BenCMMcKieSCitalopram modulation of neuronal responses to aversive face emotions: A functional MRI studyNeuroreport20071813135113551:CAS:528:DC%2BD2sXpvVajtrk%3D10.1097/WNR.0b013e328274211517762711 – reference: CremersHLeeRKeedySPhanKLCoccaroEEffects of escitalopram administration on face processing in intermittent explosive disorder: An fMRI StudyNeuropsychopharmacology20164125905971:CAS:528:DC%2BC2MXhtlWhsLfE10.1038/npp.2015.18726105140 – reference: MaldjianJALaurientiPJBurdetteJHPrecentral gyrus discrepancy in electronic versions of the Talairach atlasNeuroimage200421145045510.1016/j.neuroimage.2003.09.03214741682 – reference: CharnayYLégerLBrain serotonergic circuitriesDialogues Clin. Neurosci.201012447148710.31887/dcns.2010.12.4/ycharnay213194933181988 – reference: MadsenMKMc MahonBAndersenSBSiebnerHRKnudsenGMFisherPMDThreat-related amygdala functional connectivity is associated with 5-HTTLPR genotype and neuroticismSoc. Cogn. Affect Neurosci.201511114014910.1093/scan/nsv098262458374692322 – reference: Del-BenCMDeakinJFWMckieSThe effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: An fMRI studyNeuropsychopharmacology2005309172417341:CAS:528:DC%2BD2MXotFegurY%3D10.1038/sj.npp.130072815827569 – reference: ElliottRRubinszteinJSSahakianBJDolanRJThe neural basis of mood-congruent processing biases in depressionArch. Gen. Psychiatry200259759760410.1001/archpsyc.59.7.59712090812 – reference: McNair, D., Lorr, M. & Droppleman, L. Manual for the Profile of Mood States. (Service E and IT, ed.). (1992) – reference: DavisMWhalenPJThe amygdala: Vigilance and emotionMol. Psychiatry20016113341:STN:280:DC%2BD3M3ktlWrtg%3D%3D10.1038/sj.mp.400081211244481 – reference: SchneiderFGroddWWeissUFunctional MRI reveals left amygdala activation during emotionPsychiatry Res. Neuroimaging1997762–375821:STN:280:DyaK1c7ot1yksg%3D%3D10.1016/S0925-4927(97)00063-2 – reference: MurphySENorburyRO’SullivanUCowenPJHarmerCJEffect of a single dose of citalopram on amygdala response to emotional facesBr. J. Psychiatry2009194653554010.1192/bjp.bp.108.056093194782942802527 – reference: HaxbyJVHoffmanEAGobbiniMIHuman neural systems for face recognition and social communicationBiol. Psychiatry2002511596710.1016/S0006-3223(01)01330-011801231 – reference: AdolphsRWhat does the amygdala contribute to social cognition?Ann. NY Acad. Sci.20101191142612010NYASA1191...42A10.1111/j.1749-6632.2010.05445.x20392275 – reference: SelvarajSWalkerCArnoneDEffect of citalopram on emotion processing in humans: A combined 5-HT1A [11C]CUMI-101 PET and functional MRI studyNeuropsychopharmacology20184336556641:CAS:528:DC%2BC2sXhsVOrurrL10.1038/npp.2017.16628776580 – reference: MeyerJHMcMainSKennedySHDysfunctional attitudes and 5-HT2 receptors during depression and self-harmPsychiatry Interpers Biol. Process.2003160January9099 – reference: da Cunha-BangSFisherPMHjordtLVHolstKKnudsenGMAmygdala reactivity to fearful faces correlates positively with impulsive aggressionSoc. Neurosci.201914216217210.1080/17470919.2017.142126229271284 – reference: KatzBAMatankyKAviramGYovelIReinforcement sensitivity, depression and anxiety: A meta-analysis and meta-analytic structural equation modelClin. Psychol. Rev.20207710.1016/j.cpr.2020.10184232179341 – reference: NyenhuisDLYamamotoCLuchetaTTerrienAParmentierAAdult and geriatric normative data and validation of the profile of mood statesJ. Clin. Psychol.199955179861:STN:280:DyaK1M7pvV2gsQ%3D%3D10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-710100834 – reference: MüllerVIHöhnerYEickhoffSBInfluence of task instructions and stimuli on the neural network of face processing: An ALE meta-analysisCortex201810324025510.1016/j.cortex.2018.03.011296654675988961 – reference: HarmerCJCowenPJ’It’s the way that you look at it’-a cognitive neuropsychological account of SSRI action in depressionPhilos. Trans. R. Soc. B Biol. Sci.201336816152012040710.1098/rstb.2012.0407 – reference: HabelUWindischbergerCDerntlBAmygdala activation and facial expressions: Explicit emotion discrimination versus implicit emotion processingNeuropsychologia.200745102369237710.1016/j.neuropsychologia.2007.01.02317408704 – reference: FisherPMPriceJCMeltzerCCMedial prefrontal cortex serotonin 1A and 2A receptor binding interacts to predict threat-related amygdala reactivityBiol. Mood Anxiety Disord.2011111111:CAS:528:DC%2BC38Xlt12htrk%3D10.1186/2045-5380-1-2 – reference: HaahrMEFisherPMJensenCGCentral 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: A [11C]SB207145 PET studyMol. Psychiatry20141944274321:CAS:528:DC%2BC3sXhslCrtL%2FO10.1038/mp.2013.14724189342 – reference: LansnerJJensenCGPetersenAThree weeks of SSRI administration enhances the visual perceptual threshold—A randomized placebo-controlled studyPsychopharmacology (Berl)20192366175917691:CAS:528:DC%2BC1MXlvVGhs7o%3D10.1007/s00213-018-5158-330623228 – reference: FisherPMMadsenMKMc MahonBThree-week bright-light intervention has dose-related effects on threat-related corticolimbic reactivity and functional couplingBiol. Psychiatry201476433233910.1016/j.biopsych.2013.11.03124439303 – reference: DerntlBHabelURobinsonSAmygdala activation during recognition of emotions in a foreign ethnic group is associated with duration of staySoc. Neurosci.20094429430710.1080/1747091080257163319479638 – reference: MaldjianJALaurientiPJKraftRABurdetteJHAn automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data setsNeuroimage20031931233123910.1016/S1053-8119(03)00169-112880848 – reference: MeyerJHHouleSSagratiSBrain serotonin transporter binding potential measured with Carbon11–labeled DASB positron emission tomographyArch. Gen. Psychiatry2004611212711:CAS:528:DC%2BD2MXjt1Kmtw%3D%3D10.1001/archpsyc.61.12.127115583118 – reference: ArceESimmonsANLoveroKSteinMBPaulusMPEsctilaopram effects on insula and amygdala BOLD during emotional processiengPsychopharmachology (Berl)200819646616721:CAS:528:DC%2BD1cXhvFykurw%3D10.1007/s00213-007-1004-8.Escitalopram – reference: ElliottMLKnodtARIrelandDWhat is the test-retest reliability of common task-functional MRI measures? New empirical evidence and a meta-analysisPsychol. Sci.202031779280610.1177/0956797620916786324891417370246 – reference: FisherPMOzenneBGanzMEmotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm studyJ. Psychopharmacol.20223656266361:CAS:528:DC%2BB38Xht12gurrN10.1177/0269881122108903535549538 – reference: Fusar-PoliPPlacentinoACarlettiFFunctional atlas of emotional faces processing: A voxel-based meta-analysis of 105 functional magnetic resonance imaging studiesJ. Psychiatry Neurosci.2009346418432199497182783433 – reference: PlichtaMMSchwarzAJGrimmOTest-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test batteryNeuroimage20126031746175810.1016/j.neuroimage.2012.01.12922330316 – reference: SaidCPHaxbyJVTodorovABrain systems for assessing the affective value of facesPhilos. Trans. R. Soc. B Biol. Sci.201136615711660167010.1098/rstb.2010.0351 – reference: Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R. & Jacobs, G. A. Manual for the State-Trait Anxiety Inventory. (1983). – reference: HarmerCJMackayCEReidCBCowenPJGoodwinGMAntidepressant drug treatment modifies the neural processing of nonconscious threat cuesBiol. Psychiatry20065998168201:CAS:528:DC%2BD28XjsFOnt7w%3D10.1016/j.biopsych.2005.10.01516460693 – reference: FisherPMHaahrMEJensenCGFrokjaerVGFluctuations in [11 C] SB207145 PET binding associated with change in threat-related amygdala reactivity in humansNeuropsychopharmacology2015406151015181:CAS:528:DC%2BC2MXhvVOmtr4%3D10.1038/npp.2014.339255602014397409 – reference: SharpTBarnesNMCentral 5-HT receptors and their function; present and futureNeuropharmacology.20201771:CAS:528:DC%2BB3cXhs1ylu7%2FO10.1016/j.neuropharm.2020.10815532522572 – reference: Taylor TavaresJVClarkLFureyMLWilliamsGBSahakianBJDrevetsWCNeural basis of abnormal response to negative feedback in unmedicated mood disordersNeuroimage20084231118112610.1016/j.neuroimage.2008.05.04918586109 – reference: RobertsCSahakianBJRobbinsTWPsychological mechanisms and functions of 5-HT and SSRIs in potential therapeutic change: Lessons from the serotonergic modulation of action selection, learning, affect, and social cognitionNeurosci. Biobehav. Rev.202011913816710.1016/j.neubiorev.2020.09.00132931805 – reference: HarmerCJGoodwinGMCowenPJWhy do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug actionBr. J. Psychiatry200919510210810.1192/bjp.bp.108.05119319648538 – reference: LuckiIThe spectrum of behaviors influenced by serotoninBiol. Psychiatry19984431511621:CAS:528:DyaK1cXlsVOhsb8%3D10.1016/S0006-3223(98)00139-59693387 – reference: CowenASauterDTracyJLKeltnerDMapping the passions: Toward a high-dimensional taxonomy of emotional experience and expressionPsychol. Sci. Public Interest2019201699010.1177/1529100619850176313136376675572 – reference: RaoNThe clinical pharmacokinetics of escitalopramClin. Pharmacokinet.20074642812901:CAS:528:DC%2BD2sXlt1Grsrs%3D10.2165/00003088-200746040-0000217375980 – reference: DozoisDJADobsonKSAhnbergJLA psychometric evaluation of the beck depression inventory-IIPsychol. Assess.1998102838910.1037/1040-3590.10.2.83 – reference: RhodesRAMurthyNVDresnerMAHuman 5-HT transporter availability predicts amygdala reactivity in vivoJ. Neurosci.20072734923392371:CAS:528:DC%2BD2sXhtVSnsLfN10.1523/JNEUROSCI.1175-07.2007177153586672189 – reference: KhanABrodheadAESchwartzKAKoltsRLBrownWASex differences in antidepressant response in recent antidepressant clinical trialsJ. Clin. Psychopharmacol.200525431832410.1097/01.jcp.0000168879.03169.ce16012273 – reference: KasperSSpadoneCVerpillatPAngstJOnset of action of escitalopram compared with other antidepressants: Results of a pooled analysisInt. Clin. Psychopharmacol.200621210511010.1097/01.yic.0000194375.42589.c316421462 – reference: ArmourCMűllerováJElhaiJDA systematic literature review of PTSD’s latent structure in the diagnostic and statistical manual of mental disorders: DSM-IV to DSM-5Clin. Psychol. Rev.201644607410.1016/j.cpr.2015.12.00326761151 – reference: ElliottRZahnRDeakinJFWWAndersonIMAffective cognition and its disruption in mood disordersNeuropsychopharmacology201136115318210.1038/npp.2010.7720571485 – reference: MaronEWallMNorburyREffect of short-term escitalopram treatment on neural activation during emotional processingJ. Psychopharmacol.201630133391:CAS:528:DC%2BC28XhsVCktL3O10.1177/026988111562046226645207 – reference: TakahashiHYahataNKoedaMEffects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI studyNeuroimage2005274991100110.1016/j.neuroimage.2005.05.03915978846 – reference: CohenSJanicki-DevertsDWho’s stressed? Distributions of psychological stress in the United States in probability samples from 1983, 2006, and 2009J. Appl. Soc. Psychol.20124261320133410.1111/j.1559-1816.2012.00900.x – volume: 61 start-page: 1271 issue: 12 year: 2004 ident: 51448_CR30 publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.61.12.1271 – volume: 77 year: 2020 ident: 51448_CR62 publication-title: Clin. Psychol. Rev. doi: 10.1016/j.cpr.2020.101842 – volume: 31 start-page: 792 issue: 7 year: 2020 ident: 51448_CR69 publication-title: Psychol. Sci. doi: 10.1177/0956797620916786 – ident: 51448_CR51 – volume: 19 start-page: 427 issue: 4 year: 2014 ident: 51448_CR67 publication-title: Mol. Psychiatry doi: 10.1038/mp.2013.147 – volume: 44 start-page: 151 issue: 3 year: 1998 ident: 51448_CR20 publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(98)00139-5 – volume: 36 start-page: 626 issue: 5 year: 2022 ident: 51448_CR35 publication-title: J. Psychopharmacol. doi: 10.1177/02698811221089035 – ident: 51448_CR1 – volume: 55 start-page: 79 issue: 1 year: 1999 ident: 51448_CR57 publication-title: J. Clin. Psychol. doi: 10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-7 – volume: 4 start-page: 294 issue: 4 year: 2009 ident: 51448_CR12 publication-title: Soc. Neurosci. doi: 10.1080/17470910802571633 – volume: 13 start-page: 1787 issue: 10 year: 2015 ident: 51448_CR18 publication-title: CNS Neurol. Disord. Drug Targets doi: 10.2174/1871527313666141130205713 – volume: 238 start-page: 1265 issue: 5 year: 2020 ident: 51448_CR34 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-019-05448-0 – volume: 27 start-page: 991 issue: 4 year: 2005 ident: 51448_CR44 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2005.05.039 – volume: 30 start-page: 33 issue: 1 year: 2016 ident: 51448_CR46 publication-title: J. Psychopharmacol. doi: 10.1177/0269881115620462 – volume: 34 start-page: 418 issue: 6 year: 2009 ident: 51448_CR5 publication-title: J. Psychiatry Neurosci. – volume: 42 start-page: 1118 issue: 3 year: 2008 ident: 51448_CR63 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2008.05.049 – volume: 1 start-page: 1 issue: 1 year: 2011 ident: 51448_CR23 publication-title: Biol. Mood Anxiety Disord. doi: 10.1186/2045-5380-1-2 – volume: 119 start-page: 138 year: 2020 ident: 51448_CR22 publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2020.09.001 – volume: 59 start-page: 816 issue: 9 year: 2006 ident: 51448_CR45 publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2005.10.015 – volume: 84 start-page: 22 year: 2015 ident: 51448_CR55 publication-title: J. Psychosom. Res. doi: 10.1016/j.jpsychores.2016.03.009 – volume: 36 start-page: 153 issue: 1 year: 2011 ident: 51448_CR16 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2010.77 – volume: 195 start-page: 102 year: 2009 ident: 51448_CR33 publication-title: Br. J. Psychiatry doi: 10.1192/bjp.bp.108.051193 – volume: 177 year: 2020 ident: 51448_CR21 publication-title: Neuropharmacology. doi: 10.1016/j.neuropharm.2020.108155 – volume: 160 start-page: 90 issue: January year: 2003 ident: 51448_CR26 publication-title: Psychiatry Interpers Biol. Process. – volume: 53 start-page: S377 issue: April year: 2021 ident: 51448_CR27 publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2021.10.484 – volume: 11 start-page: 140 issue: 1 year: 2015 ident: 51448_CR29 publication-title: Soc. Cogn. Affect Neurosci. doi: 10.1093/scan/nsv098 – volume: 43 start-page: 655 issue: 3 year: 2018 ident: 51448_CR36 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2017.166 – volume: 368 start-page: 20120407 issue: 1615 year: 2013 ident: 51448_CR19 publication-title: Philos. Trans. R. Soc. B Biol. Sci. doi: 10.1098/rstb.2012.0407 – volume: 49 start-page: 1161 issue: 2 year: 2010 ident: 51448_CR39 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2009.10.013 – volume: 59 start-page: 597 issue: 7 year: 2002 ident: 51448_CR64 publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.59.7.597 – volume: 25 start-page: 318 issue: 4 year: 2005 ident: 51448_CR48 publication-title: J. Clin. Psychopharmacol. doi: 10.1097/01.jcp.0000168879.03169.ce – volume: 12 start-page: 471 issue: 4 year: 2010 ident: 51448_CR31 publication-title: Dialogues Clin. Neurosci. doi: 10.31887/dcns.2010.12.4/ycharnay – volume: 42 start-page: 1320 issue: 6 year: 2012 ident: 51448_CR61 publication-title: J. Appl. Soc. Psychol. doi: 10.1111/j.1559-1816.2012.00900.x – volume: 76 start-page: 332 issue: 4 year: 2014 ident: 51448_CR58 publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2013.11.031 – volume: 21 start-page: 450 issue: 1 year: 2004 ident: 51448_CR60 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2003.09.032 – volume: 41 start-page: 590 issue: 2 year: 2016 ident: 51448_CR37 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2015.187 – volume: 46 start-page: 281 issue: 4 year: 2007 ident: 51448_CR50 publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-200746040-00002 – volume: 30 start-page: 1724 issue: 9 year: 2005 ident: 51448_CR41 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300728 – volume: 6 start-page: 13 issue: 1 year: 2001 ident: 51448_CR11 publication-title: Mol. Psychiatry doi: 10.1038/sj.mp.4000812 – volume: 236 start-page: 1759 issue: 6 year: 2019 ident: 51448_CR70 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-018-5158-3 – volume: 44 start-page: 60 year: 2016 ident: 51448_CR9 publication-title: Clin. Psychol. Rev. doi: 10.1016/j.cpr.2015.12.003 – volume: 103 start-page: 240 year: 2018 ident: 51448_CR15 publication-title: Cortex doi: 10.1016/j.cortex.2018.03.011 – volume: 27 start-page: 903 issue: 10 year: 2015 ident: 51448_CR25 publication-title: J. Pharmacol. Pharomotherapeutics. doi: 10.1177/0269881113494106.Acute – volume: 21 start-page: 105 issue: 2 year: 2006 ident: 51448_CR32 publication-title: Int. Clin. Psychopharmacol. doi: 10.1097/01.yic.0000194375.42589.c3 – volume: 20 start-page: 69 issue: 1 year: 2019 ident: 51448_CR3 publication-title: Psychol. Sci. Public Interest doi: 10.1177/1529100619850176 – volume: 366 start-page: 1660 issue: 1571 year: 2011 ident: 51448_CR4 publication-title: Philos. Trans. R. Soc. B Biol. Sci. doi: 10.1098/rstb.2010.0351 – volume: 10 start-page: 83 issue: 2 year: 1998 ident: 51448_CR52 publication-title: Psychol. Assess. doi: 10.1037/1040-3590.10.2.83 – volume: 18 start-page: 1351 issue: 13 year: 2007 ident: 51448_CR40 publication-title: Neuroreport doi: 10.1097/WNR.0b013e3282742115 – volume: 48 start-page: 3416 issue: 12 year: 2010 ident: 51448_CR6 publication-title: Neuropsychologia doi: 10.1016/j.neuropsychologia.2010.06.038 – volume: 12 start-page: 169 issue: 2 year: 2009 ident: 51448_CR42 publication-title: Int. J. Neuropsychopharmacol. doi: 10.1017/S1461145708009164 – volume: 45 start-page: 2369 issue: 10 year: 2007 ident: 51448_CR14 publication-title: Neuropsychologia. doi: 10.1016/j.neuropsychologia.2007.01.023 – ident: 51448_CR56 – volume: 196 start-page: 661 issue: 4 year: 2008 ident: 51448_CR47 publication-title: Psychopharmachology (Berl) doi: 10.1007/s00213-007-1004-8.Escitalopram – volume: 20 start-page: 1 issue: 1 year: 2020 ident: 51448_CR54 publication-title: BMC Med. Res. Methodol. doi: 10.1186/s12874-020-00982-4 – ident: 51448_CR53 doi: 10.1037/t06496-000 – volume: 76 start-page: 75 issue: 2–3 year: 1997 ident: 51448_CR13 publication-title: Psychiatry Res. Neuroimaging doi: 10.1016/S0925-4927(97)00063-2 – year: 2023 ident: 51448_CR49 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-022-01523-x – volume: 60 start-page: 1746 issue: 3 year: 2012 ident: 51448_CR68 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.01.129 – volume: 40 start-page: 1510 issue: 6 year: 2015 ident: 51448_CR24 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2014.339 – volume: 2 start-page: 303 issue: 4 year: 2007 ident: 51448_CR65 publication-title: Soc. Cogn. Affect. Neurosci. doi: 10.1093/scan/nsm029 – volume: 161 start-page: 126 issue: 1 year: 2007 ident: 51448_CR10 publication-title: J. Neurosci. Methods doi: 10.1016/j.jneumeth.2006.10.016 – volume: 30 start-page: 1441 issue: 4 year: 2006 ident: 51448_CR8 publication-title: NeuroImage (Orlando, Fla) – volume: 27 start-page: 9233 issue: 34 year: 2007 ident: 51448_CR28 publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.1175-07.2007 – volume: 19 start-page: 1233 issue: 3 year: 2003 ident: 51448_CR59 publication-title: Neuroimage doi: 10.1016/S1053-8119(03)00169-1 – volume: 14 start-page: 162 issue: 2 year: 2019 ident: 51448_CR17 publication-title: Soc. Neurosci. doi: 10.1080/17470919.2017.1421262 – volume: 51 start-page: 59 issue: 1 year: 2002 ident: 51448_CR2 publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(01)01330-0 – volume: 124 start-page: 1213 year: 2016 ident: 51448_CR71 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2015.04.025 – volume: 33 start-page: 3221 issue: 13 year: 2008 ident: 51448_CR38 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.52 – volume: 1191 start-page: 42 issue: 1 year: 2010 ident: 51448_CR7 publication-title: Ann. NY Acad. Sci. doi: 10.1111/j.1749-6632.2010.05445.x – volume: 194 start-page: 535 issue: 6 year: 2009 ident: 51448_CR43 publication-title: Br. J. Psychiatry doi: 10.1192/bjp.bp.108.056093 – volume: 1 start-page: 1 issue: 1 year: 2011 ident: 51448_CR66 publication-title: Biol. Mood Anxiety Disord. doi: 10.1186/2045-5380-1-10
SSID	ssj0000529419
Score	2.423315
Snippet	Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how SSRI... Abstract Short-term intake of selective serotonin reuptake inhibitors (SSRIs) modulates threat-related amygdala responses in healthy individuals. However, how...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	3149
SubjectTerms	631/154/436 631/378/1457 631/378/2649 Amygdala Brain mapping Brain research Citalopram Clinical trials Cognition & reasoning Emotions Face Females Functional magnetic resonance imaging Health care Hospitals Humanities and Social Sciences Investigations Mood multidisciplinary NCT NCT04239339 Placebos Science Science (multidisciplinary) Serotonin Serotonin uptake inhibitors
SummonAdditionalLinks	– databaseName: Science Database (ProQuest) dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFNzRQkJG4UatO4iQ2FwSIFQeoeuiht8iPMV11SbabLKg_iv_I2MmmWh69cItiJ3KSzzNf5knIK15mRigLDLWLZaIqNNNFaZk3rkSForT1MVH4c3V4KE9O1NFocOvGsMqNTIyC2rU22MgPssBEZNCQb5fnLHSNCt7VsYXGdXIDmU0aQrq-ZEeTjSV4sUSqxlwZnsuDDvVVyCnLBEOmIBAkW_oolu3_G9f8M2TyN79pVEezu__7IPfInZGI0ncDcu6Ta9A8ILeG1pQXD8nPGSq8wU5ITWgjQVdDNC10tG8pDN1_cNCHmC4aW43THoEBYdijDKU_AM462no6b3p9BuEIUOEGc9Fypb_haTpkYV7Q-ZQW1r2hmrp2bRbADFJgt09j2Jhp2RhVvwBHUcG6FhGKh7E-7iNyPPt4_OETG1s7MFuItGemFEaCqIDbAkruHWLGeqVTk3uXA4oaL4VQyN6UkFyqFHKX54Xm2lYFQP6Y7DRtA7uEQqp5pqtSO7yfskIZq0I-MP7ZW2XTIiHp5vvWdix7HrpvLOrofs9lPWCiRkzUERN1lpDX0zXLoejHlbPfB9hMM0PB7niiXX2tx_1fOy-RSHEOWntRVNZkFZeV9j60efMmTcjeBi31KEW6-hIqCXk5DePbDU4d3UC7HuYg5Ss4T8iTAaPTSnIU10gocYVyC71bS90eaeanscZ4SErBm8qE7G-Afrmuf7-Lp1c_xjNyOwt7L0S9V3tkp1-t4Tm5ab_38271Im7eXzHST0M priority: 102 providerName: ProQuest
Title	Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study
URI	https://link.springer.com/article/10.1038/s41598-024-51448-2 https://www.ncbi.nlm.nih.gov/pubmed/38326352 https://www.proquest.com/docview/2923180066 https://www.proquest.com/docview/2923910500 https://pubmed.ncbi.nlm.nih.gov/PMC10850508 https://doaj.org/article/df824400eaaf457cb27087aff1030fb1
Volume	14
WOSCitedRecordID	wos001158921600022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgFyQuiDeBpTISNzZaJ3FimxuLtgKJrSq0h3KKbGcsqi3JqmlB-6P4j4zttGx5XrhYlu1EI8_Y89meByEvWJUbriykqF1sykWpU11WNnWmqVChKG1dcBR-LyYTOZup6ZVUX94mLIYHjhN31DiJGogx0NrxUliTCyaFds7nx3ImHHyYUFcOUzGqd654pgYvGVbIox41lfcmy3mKGIGjeOxoohCw_3co81djyZ9eTIMiGt8htwcESV9Hyu-Sa9DeIzdjTsnL--TbGDVVvOCjxud_oMtoBgs9XXUUYtoe7HTeGIuGHOF0hRwF3-1w86NfAc572jk6b1f6HHwNUFP6e56Lpf6MzTS6T17S-dafq39FNW26tVlAahC7Noc02HuZLh3M4RfQUNSMTYeihdUQ2PYBORufnL15mw45GVJb8myVmoobCVwAsyVUzDXIbOuUzkzhmgJwj3CSc4WwS3HJpMqgaIqi1ExbUQIUD8le27XwmFDINMu1qHSD_1OWK2OVd-TFI7lVNisTkm3YU9shXrlPm7Gow7t5IevI0hpZWgeW1nlCXm6_uYjROv46-thzfTvSR9oODSh_9SB_9b_kLyEHG5mph-Xf17mHzdLDuYQ833bj7PrXGN1Ct45jEKuVjCXkURSxLSUF7rOIBJFCuSN8O6Tu9rTzTyE4uPcmwZ_KhBxu5PQHXX-eiyf_Yy6eklu5X2DeqF0ckL3Vcg3PyA37ZTXvlyNyXcxEKOWI7B-fTKYfRmHVYnmaT30psNyfvjudfvwOpo5Imw
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKAcGFZ4FAASPBiUZ1EiexkRDitWrVZdVDD71ZtmPDqkuybLJU-6P6Hxk7j2p59NYDtyj2WrPeb2a-teeB0EuSxYpybULwLjqkeSpDmWY6tKrIwKFwqa1PFB7nkwk7PuaHG-isz4VxYZW9TfSGuqi0OyPfjR0TYc5Dvpv_CF3XKHe72rfQaGFxYFan8Jetfrv_CX7fV3E8-nz0cS_sugqEOqVRE6qMKmZobohOTUZsAeJqy2WkElskBlBuGaUciAOnjDAemaRIklQSqfPUmASWvYKuUldYzEUKxofDkY67NKMR71JzSMJ2a3CPLoUtpiEQEwqYXHN_vkvA36jtnxGav13Teu83uv2f7dsddKuj2fh9qxd30YYp76HrbePN1X10NgJ33p6CYuWaZOBFGytsatxU2LS9jWDQuog17Bup4wZgb9ywBQ-BT405qXFl8bRs5IlxTwbohDsMmy_kd3iN2xzTFZ4OSW_1GyxxUS3VzIQKCH6xg31QnKrCLmdgZgoM9KGoQP_g0Vf_3UJHl7FVD9BmWZXmEcImkiSWeSYLWI9rypXmLtuZMaa5jtIART2chO6KurveIjPhgwsSJloICoCg8BAUcYBeD5-ZtyVNLpz9waF0mOnKkfsX1eKr6KybKCwDmkiIkdLSNNcqzgnLpbWuiZ1VUYC2e3CKzkbW4hyZAXoxDMPuuisrWZpq2c4BQpsSEqCHrUoMkiTgjIAug4RsTVnWRF0fKafffAV1l3IDi7IA7fR6dS7Xv_fi8cVf4zm6sXf0ZSzG-5ODJ-hm7NTexffn22izWSzNU3RN_2ym9eKZtxsYiUvWt18gyarD
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGB4gXrgMCA4wETyyqkziJjYQQMCqqjaoPexhPlu3YUK0kpUmZ-qP4Afw7jnObymVve-Atil3r1D2Xr_Y550PoGUlCRbk2PkQX7dM0lr6ME-1blSUQULjUti4UPkwnE3Z8zKdb6GdXC-PSKjufWDvqrNDujHwYOiTCXIQc2jYtYro_er345jsGKXfT2tFpNCpyYNan8PetfDXeh9_6eRiO3h-9--C3DAO-jmlQ-SqhihmaGqJjkxCbgejachmoyGaRAY23jFIOIIJTRhgPTJRFUSyJ1GlsTATLXkLbgMhpOEDb0_HH6af-gMddodGAt4U6JGLDEoKlK2gLqQ8whYKGbgTDmjPgb0D3z3zN3y5t61g4uvEf7-JNdL0F4PhNYzG30JbJb6MrDSXn-g76MYJA35yPYuXoM_CyySI2Ja4KbBrWIxi0LpcN1xTruAKDMG7YQuzAp8aclLiweJZX8sS4JwNAwx2TLZbyK7zGTfXpGs_6crjyJZY4K1ZqbnwF0D_bw3W6nCr8tppgbjIMwCIrwDLhse4LvIOOLmKr7qJBXuTmPsImkCSUaSIzWI9rypXmrg6aMaa5DmIPBZ1qCd22e3esI3NRpx1ETDTqKEAdRa2OIvTQi_4zi6bZybmz3zqN7We6RuX1i2L5WbR-T2SWAYAkxEhpaZxqFaaEpdJaR29nVeCh3U5RRes9S3GmpR562g_D7rrLLJmbYtXMAagbE-Khe4159JJEEKYASIOEbMNwNkTdHMlnX-re6q4YBxZlHtrrbOxMrn_vxYPzv8YTdBXMTByOJwcP0bXQeQCX-J_uokG1XJlH6LL-Xs3K5ePWiWAkLtjgfgG0ibUM
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Functional+brain+responses+to+emotional+faces+after+three+to+five+weeks+of+intake+of+escitalopram+in+healthy+individuals%3A+a+double-blind%2C+placebo-controlled+randomised+study&rft.jtitle=Scientific+reports&rft.au=Sophia+Armand&rft.au=Christelle+Langley&rft.au=Annette+Johansen&rft.au=Brice+Ozenne&rft.date=2024-02-07&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft.spage=1&rft.epage=12&rft_id=info:doi/10.1038%2Fs41598-024-51448-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_df824400eaaf457cb27087aff1030fb1
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon